CLIMATE-FORUM-RY
The greenhouse effect, according to the IPCC, is due to the longwave absorption of 156 Wm-2 by greenhouse gases and partly by clouds. This absorption flux should be able to reradiate back to the Earth 346 Wm-2 , which is impossible according to the energy conservation laws of physics. The overall effect of greenhouse gases is about 50% lower than the prevailing theory.
Other energy sources beside longwave radiation absorption are shortwave radiation absorption by the greenhouse gases and latent and sensible heating. Together, these four energy sources perfectly explain the reradiation flux by the atmosphere on the Earth’s surface. The total absorption contribution of 2.4 °C by carbon dioxide (CO2 ) of 400 ppm means that the carbon dioxide warming effect of the IPCC’s calculations is about 200% too high.
“The portions of individual contributors are: water 45.6%, latent heating 30.8%, sensible heating 8.2%, carbon dioxide 7.3%, ozone 6.1%, clouds 0.9%, methane & nitrogen oxide 0.7% and aerosols 0.3%. The cloud effect is minimal, and it differs from other earlier studies (19% and 39%) because these studies do not consider the reduction of solar insolation by clouds,” said Ollila.
The reproduction of the radiative forcing by CO2 gave a 41.6% lower value for 560 ppm than the same of the IPCC. The radiative forcing values are transformed into warming values by the climate sensitivity parameter (CSP). The CSP value of the IPCC is 0.5 K/(Wm-2 ), which includes so-called positive water feedback, and which doubles the warming effects of greenhouse gases. According to this study, the CSP value is 0.27 K/(Wm-2 ). The direct humidity and temperature observations confirm that there is no positive water feedback in the atmosphere,” said Ollila.
“The warming effect of CO2 , according to the radiative forcing equation and the CSP value of this study, can be nicely fitted into the overall greenhouse effect of CO2 , but it is not the case in the simple model of the IPCC,” said Ollila.
Journal Reference :
Ollila, Antero. Challenging the greenhouse effect specification and the climate sensitivity of the IPCC . Physical Science International Journal, 22(2): 1-19, 2019. http://www.journalpsij.com/index.php/PSIJ/article/view/30127/56520
View source version on businesswire.com: https://www.businesswire.com/news/home/20190527005324/en/
Contact:
Climate Forum ry Dr. Antero Ollila, Adjunct Associate Professor, Emeritus tel. +358442437365 aveollila@yahoo.com Link
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Altris and Draslovka Partner to Scale Europe’s First Sodium-Ion Battery Technology Supply Chain15.1.2026 14:00:00 CET | Press release
Altris, a Swedish sodium-ion battery developer, and Draslovka, a global leader in specialty chemicals, have entered a strategic partnership to build Europe’s first industrial-scale sodium-ion cathode value chain. Under the comprehensive agreement that includes a total 19.3 MEUR in-kind investment by Draslovka in Altris, the two companies will scale fully connected production of Altris’ patented sodium-ion cathode active material (CAM) at Draslovka’s facility in Kolín, Czech Republic, supplying up to 350 tonnes of CAM annually. Draslovka and Altris are partnering to convert an existing line at Draslovka’s Kolín facility for production of Altris’ sodium-ion CAM, enabling rapid time-to-market and capital-efficient scale-up. Once ramped, the line will support production of up to 350 tonnes annually – a European-controlled supply equivalent to around 175 MWh of sodium-ion cell capacity. As part of the agreement, Draslovka is making a new in‑kind 19.3 MEUR strategic investment in Altris to c
CPP Investments Increases Commitment to Canadian Market through Northleaf Capital Partners15.1.2026 14:00:00 CET | Press release
Canada Pension Plan Investment Board (CPP Investments) and Northleaf Capital Partners (Northleaf) today announced a significant expansion of their longstanding Canadian investment partnership, supporting the growth and scaling of domestic private companies. CPP Investments has committed to invest an additional C$750 million through its established Canadian mid-market program managed by Northleaf, bringing CPP Investments’ cumulative commitments to the manager to more than C$3 billion since inception. The customized mandate focuses on maximizing net returns through a diversified strategy that includes primary fund commitments to small and mid-market Canadian buyout funds, secondary investments, and direct co-investments focused on the domestic market. “There are compelling investment opportunities in the Canadian market, and our two-decade long partnership with Northleaf has proven to be an effective and scalable way to invest in homegrown businesses with patient, long-term capital,” sa
Vantage Data Centers Completes £200M Tap of Existing £600M Industry-First EMEA Data Center Asset-Backed Securitization (ABS) and Adds New £54M Class B Tranche15.1.2026 14:00:00 CET | Press release
Financing will support the company’s expansion across EMEA to keep pace with AI and cloud demand Vantage Data Centers, a leading global provider of hyperscale data center campuses, today announced it has raised an additional £254 million in securitized term notes. £200 million was raised through a tap of the existing Class A-2 Notes while £54 million was raised from the new Class B Tranche. This builds on Vantage’s debut public issuance in 2024 raising £600 million, which was the first-ever EMEA data center ABS completed in sterling. The Class A-2 Notes are rated A-, A (low) and A by Standard & Poor’s, Morningstar DBRS and Scope Ratings, respectively. The Class B Notes are rated BBB- by Standard & Poor’s and BBB by Morningstar DBRS and Scope Ratings. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260115777091/en/ Vantage’s 148MW Cardiff, Wales, campus is one of Europe’s largest hyperscale data center campuses. The new notes
QPS Selects Oracle Argus Safety Database to Enhance Pharmacovigilance in Clinical Trials15.1.2026 13:57:00 CET | Press release
QPS Holdings, LLC (QPS), an award-winning contract research organization (CRO) focused on bioanalysis and clinical trials announces the successful implementation of Oracle Argus, a premier pharmacovigilance system designed to support comprehensive safety case management for clinical trials. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260115711485/en/ Derek Grimes, EVP, Global Head of Clinical Research at QPS Holdings, LLC. The adoption of the Oracle Argus drug safety platform underscores QPS’s commitment to advancing patient safety, regulatory compliance, and operational excellence across its clients’ clinical drug development programs. Integrating this industry-standard safety platform strengthens QPS’ ability to capture, manage, and report adverse events in accordance with global regulatory requirements. “Ensuring patient safety and data integrity is at the heart of what we do when conducting clinical trials,” said Dere
InterAx and Alveus Announce Strategic Research and Licensing Agreement to Develop Differentiated Therapeutic Candidate for Metabolic Disease15.1.2026 13:30:00 CET | Press release
InterAx Biotech Ltd (“InterAx”) and Alveus Therapeutics Inc. (“Alveus”) today announced a strategic research collaboration and licensing agreement to develop a differentiated small molecule candidate for metabolic disease to deliver durable weight loss with superior tolerability. This partnership forms a joint research effort on a target and modality of established but untapped therapeutic interest by combining InterAx’s Deep Signal™ discovery platform – designed to optimize candidates toward superior signaling profiles – with Alveus’s deep R&D expertise and leadership in obesity, diabetes, and cardiometabolic disease. While financial terms remain undisclosed, the agreement includes an upfront payment and eligibility for future development, regulatory, and commercial milestones. “We are thrilled to join forces with Alveus to advance a highly differentiated therapeutic candidate designed to overcome the limitations of today’s obesity medications,” said Andrew Roberts, CEO of InterAx. “O
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom